Clinical Trial Detail

NCT ID NCT04482309
Title A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors AstraZeneca
Indications

ovary epithelial cancer

endometrial cancer

pancreatic cancer

urinary bladder cancer

biliary tract cancer

cervical cancer

Advanced Solid Tumor

Therapies

Trastuzumab deruxtecan

Age Groups: adult senior

Additional content available in CKB BOOST